Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-06-27

FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application from Prasco Laboratories for a generic version of levetiracetam.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVETIRACETAM (levetiracetam)

Snippet

SUPPL AP for LEVETIRACETAM (LEVETIRACETAM)